TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an update.
Biocytogen Pharmaceuticals has announced the preliminary price consultation period for its proposed issuance of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The company plans to issue 47,500,000 new A Shares, representing a significant portion of its total share capital. This move is expected to enhance the company’s financial position and market presence, potentially impacting stakeholders by increasing investment opportunities and expanding its shareholder base.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a pharmaceutical company based in China, focusing on the development and commercialization of innovative drugs. The company is involved in biopharmaceutical research and development, with a market focus on providing advanced therapeutic solutions.
Average Trading Volume: 488,942
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.33B
Find detailed analytics on 2315 stock on TipRanks’ Stock Analysis page.